報價延遲最少15分鐘:2024/11/01 01:17 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
174 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
7.93/17.80
|
|
企業價值
33.58B
|
| 資產負債 |
|
每股賬面淨值
109.08
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
9.84B
|
|
每股收益
68.61
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/01 01:17 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. |